Literature DB >> 15068624

Lack of correlation for sodium iodide symporter mRNA and protein expression and analysis of sodium iodide symporter promoter methylation in benign cold thyroid nodules.

Susanne Neumann1, Katrin Schuchardt, Andreas Reske, Alexander Reske, Peter Emmrich, Ralf Paschke.   

Abstract

Cold thyroid nodules (CTNs) are characterized by a reduced iodide uptake in comparison to normal thyroid tissue. The sodium iodide symporter (NIS) is the first step in thyroid hormone synthesis and mediates the active iodide transport in the thyroid cells suggesting that decreased iodide uptake could be a result of changes in NIS expression or molecular defects in the NIS gene. In contrast to previous studies, an intraindividual comparison of NIS mRNA expression in CTNs and their corresponding surrounding tissue was performed using direct detection of NIS mRNA. A significant reduction in NIS mRNA expression was detected in 86% of the 14 investigated CTNs. We hypothesized that human sodium iodide symporter (hNIS) transcriptional failure could be caused by primary molecular NIS gene defects and/or methylation of DNA in the NIS promoter. However, no mutation in the NIS cDNA nor in the NIS promoter region upstream up to-443 bp from the ATG start codon was detected. Therefore, primary molecular NIS gene defects were excluded. However, in 50% of CTNs with reduced NIS mRNA expression, the promoter region was hypermethylated. NIS mRNA expression in these hypermethylated CTNs only reached a maximum of 30% of the corresponding surrounding tissue. Hence, methylation of CpG islands in the NIS promotor could be a regulatory mechanism of NIS transcription in CTNs. Immunoblot revealed absent hNIS protein expression in the total cell membrane fraction in 45% of investigated nodules. In the majority of the remaining CTNs NIS protein expression was decreased in the nodule tissue compared to the corresponding surrounding tissue. For investigating protein expression immunhistochemistry has two advantages. First, the whole nodule area can be investigated, and second, NIS expression can be detected in areas where an immunoblot of a cell membrane fraction is negative. Interestingly, immunhistochemistry revealed higher NIS expression in 50% of CTNs compared to their corresponding surrounding tissues and NIS staining was predominantly intracellular. These data demonstrate that NIS protein expression does not reflect NIS mRNA expression. Therefore, factors that affect targeting of NIS to the plasma membrane are likely to be affected.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15068624     DOI: 10.1089/105072504322880337

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  12 in total

Review 1.  The biology of the sodium iodide symporter and its potential for targeted gene delivery.

Authors:  Mohan Hingorani; Christine Spitzweg; Georges Vassaux; Kate Newbold; Alan Melcher; Hardev Pandha; Richard Vile; Kevin Harrington
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

2.  5-aza-2'-deoxycytidine has minor effects on differentiation in human thyroid cancer cell lines, but modulates genes that are involved in adaptation in vitro.

Authors:  Geneviève Dom; Vanessa Chico Galdo; Maxime Tarabichi; Gil Tomás; Aline Hébrant; Guy Andry; Viviane De Martelar; Frédérick Libert; Emmanuelle Leteurtre; Jacques E Dumont; Carine Maenhaut; Wilma C G van Staveren
Journal:  Thyroid       Date:  2013-03       Impact factor: 6.568

3.  Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome.

Authors:  Elaine Cristina Morari; Joyce Rosário Silva; Ana Carolina Trindade Guilhen; Lucas Leite Cunha; Marjory Alana Marcello; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward
Journal:  Endocr Pathol       Date:  2010-12       Impact factor: 3.943

Review 4.  Neuropeptide B and W: neurotransmitters in an emerging G-protein-coupled receptor system.

Authors:  Gurminder Singh; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2006-07-17       Impact factor: 8.739

Review 5.  Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer.

Authors:  Tania Pilli; Kanteti V Prasad; Shankar Jayarama; Furio Pacini; Bellur S Prabhakar
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

6.  Influence of signal transducer and activator of transcription-1 signaling on thyroid morphology and function.

Authors:  Hiroaki J Kimura; Roberto Rocchi; Melissa A Landek-Salgado; Koichi Suzuki; Cindy Y Chen; Miho Kimura; Noel R Rose; Patrizio Caturegli
Journal:  Endocrinology       Date:  2009-03-26       Impact factor: 4.736

7.  Methylation levels of sodium-iodide symporter (NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression.

Authors:  A L Galrão; A K Sodré; R Y Camargo; C U Friguglietti; M A Kulcsar; E U Lima; G Medeiros-Neto; I G S Rubio
Journal:  Endocrine       Date:  2012-09-01       Impact factor: 3.633

8.  Global analysis of viral infection in an archaeal model system.

Authors:  Walid S Maaty; Joseph D Steffens; Joshua Heinemann; Alice C Ortmann; Benjamin D Reeves; Swapan K Biswas; Edward A Dratz; Paul A Grieco; Mark J Young; Brian Bothner
Journal:  Front Microbiol       Date:  2012-12-10       Impact factor: 5.640

9.  Positive radionuclide imaging of miRNA expression using RILES and the human sodium iodide symporter as reporter gene is feasible and supports a protective role of miRNA-23a in response to muscular atrophy.

Authors:  Viorel Simion; Julien Sobilo; Rudy Clemoncon; Sharuja Natkunarajah; Safia Ezzine; Florence Abdallah; Stephanie Lerondel; Chantal Pichon; Patrick Baril
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

10.  Serum 8-OHdG and HIF-1α levels: do they affect the development of malignancy in patients with hypoactive thyroid nodules?

Authors:  Harman Ece; Erdogan Mehmet; Biray Avci Cigir; Dodurga Yavuz; Karadeniz Muammer; Gunduz Cumhur; Harman Mustafa; Cetinkalp Sevki; Saygılı Fusun; Ozgen Ahmet Gokhan
Journal:  Contemp Oncol (Pozn)       Date:  2013-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.